{
    "clinical_study": {
        "@rank": "60306", 
        "acronym": "OptiLIF\u2122", 
        "arm_group": {
            "arm_group_label": "PerX360\u00ba System\u2122", 
            "description": "Patients treated with PerX360\u00ba System\u2122"
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, non-randomized post marketing surveillance registry including up to\n      125 patients treated with the PerX360\u00ba System\u2122.  Patients will receive a follow-up\n      evaluation at the per physician defined time points: at discharge, an Interim 1 visit (1\n      month), an Interim 2 visit (3-6 months) and a Final visit (12 months). Imaging obtained at\n      visits should be per standard of care."
        }, 
        "brief_title": "The PerX360\u00ba System\u2122 Registry", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "DDD", 
        "detailed_description": {
            "textblock": "For all patients participating in the registry, the following outcomes will be analyzed:\n\n        -  Change in pain score on the Visual Analog Scale(VAS) from baseline for leg pain\n\n        -  Change in pain score on the Visual Analog Scale(VAS) from baseline for back pain\n\n        -  Change in Oswestry Disability Index (ODI) score from baseline\n\n        -  Proportion of patients with a device related complication\n\n        -  Proportion of patients with lack of revision, removal, or reoperation\n\n        -  Proportion of patients with radiographic fusion"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient understands the nature of the procedure and provides written informed consent\n\n          -  Patient is willing to return to the treating physician for his/her routine follow-up\n             visits up to 12 months post treatment\n\n          -  Age > 18 years\n\n          -  Patient is treated with the Optiport\u2122 and Opticage\u2122 products\n\n        Exclusion Criteria:None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult subjects treated with the Optiport\u2122 and Opticage\u2122 products"
            }
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796535", 
            "org_study_id": "TP201"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 13, 2013", 
        "location": [
            {
                "contact": {
                    "email": "rappardnancy@gmail.com", 
                    "last_name": "Nancy Rappard", 
                    "phone": "323-857-5300", 
                    "phone_ext": "202"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90036"
                    }, 
                    "name": "Los Angeles Brain and Spine Institute"
                }, 
                "investigator": {
                    "last_name": "Dr. Rappard", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Augustine", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32086"
                    }, 
                    "name": "Flagler Hospital"
                }, 
                "investigator": {
                    "last_name": "David Greenwald, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational, Multi Center, Non-Randomized (Single Arm) Registration of the PerX360\u00ba System\u2122", 
        "overall_contact": {
            "email": "mbutler@i-spineinc.com", 
            "last_name": "Michelle Butler", 
            "phone": "858 220 6904"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Image Assessment", 
            "measure": "Fusion", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796535"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Interventional Spine, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Interventional Spine, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Case-Only", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "1 Year", 
        "verification_date": "March 2013"
    }
}